Detalhe da pesquisa
1.
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 95(5): 410-418, 2024 Apr 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37940409
2.
Eculizumab for a catastrophic relapse in NMOSD: case report.
Neurol Sci
; 45(1): 249-251, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37500991
3.
Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma.
Neurol Sci
; 45(5): 2199-2202, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38091210
4.
Design and Validation of an Expanded Disability Status Scale Model in Multiple Sclerosis.
Eur Neurol
; 85(2): 112-121, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-34788755
5.
Adding brain volume measures into response criteria in multiple sclerosis: the Río-4 score.
Neuroradiology
; 63(7): 1031-1041, 2021 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-33237430
6.
Cognitive impairment in multiple sclerosis: diagnosis and monitoring.
Neurol Sci
; 42(12): 5183-5193, 2021 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-33796947
7.
Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases.
Neurol Sci
; 38(5): 727-743, 2017 May.
Artigo
Inglês
| MEDLINE | ID: mdl-28155026
8.
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
Neurol Sci
; 38(7): 1213-1221, 2017 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-28396953
9.
Silent Progression or Bout Onset Progressive Multiple Sclerosis?
Ann Neurol
; 86(3): 472, 2019 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31251817
10.
Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation.
Brain
; 137(Pt 10): 2703-14, 2014 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-25060097
11.
Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.
Mult Scler
; 19(9): 1175-81, 2013 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-23319072
12.
Is it cost-effective to request IgM oligoclonal bands against lipids in daily practice as a biomarker for poor prognosis in multiple sclerosis?
Mult Scler Relat Disord
; 79: 105033, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37832257
13.
Improving the efficiency of free kappa light chains as diagnostic biomarker of Multiple Sclerosis by using a novel algorithm.
Mult Scler Relat Disord
; 79: 104997, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37714099
14.
Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience.
Front Neurol
; 14: 1060696, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36959824
15.
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.
JAMA Neurol
; 80(4): 397-403, 2023 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36848127
16.
Oligoclonal M bands unveil occult inflammation in multiple sclerosis.
Mult Scler Relat Disord
; 68: 104118, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-36057174
17.
High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis.
Front Immunol
; 13: 827738, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35330910
18.
Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
J Neurol
; 269(7): 3676-3681, 2022 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-35107597
19.
Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study.
Neurol Ther
; 11(3): 1101-1116, 2022 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-35524037
20.
Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis.
Front Neurol
; 13: 991596, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36388220